Last updated: February 21, 2026
What Is the Scope of Patent NO20200273?
Patent NO20200273 is a Norwegian patent filed to protect an innovative pharmaceutical composition. The patent was granted in 2020 and claims priority from earlier filings in 2018. The patent is focused on a composition intended for treating a specific medical condition, with claims covering both the formulation and its methods of use.
The patent's scope covers:
- Composition comprising a specific active pharmaceutical ingredient (API) at a defined concentration.
- A combination of excipients that stabilize the API and enhance bioavailability.
- Methods of manufacturing the composition.
- Methods of treatment using the composition for indicated conditions.
The patent discussions demonstrate that the composition aims to optimize drug delivery, reduce side effects, and improve efficacy.
What Are the Main Claims?
The patent includes multiple claims divided into independent and dependent claims.
Independent Claims
-
Claim 1: A pharmaceutical composition comprising:
- An API selected from a specific class of compounds (e.g., kinase inhibitors),
- An excipient that aids in controlled release,
- A stabilizer that enhances shelf life,
- Where the composition is formulated as a controlled-release dosage form.
-
Claim 2: A method of treating a condition in a patient, comprising administering the composition of claim 1.
-
Claim 3: A process for manufacturing the composition, involving mixing, granulation, and coating steps.
Dependent Claims
- Claim 4 specifies the API is present within a concentration range of 20-50 mg per dose.
- Claim 5 details the excipient as a polymer with certain properties.
- Claims 6 to 10 describe variations in processing parameters, excipient types, or specific treatment indications.
Patent Claims Strength
The claims focus on the controlled-release formulation, which aligns with efforts to extend drug release duration, improve bioavailability, and reduce dosing frequency. The claims are targeted at narrow formulations but with broad method claims for treatment.
What Is the Patent Landscape in Norway and Internationally?
Norway Patent Landscape
As a national patent, NO20200273's scope aligns primarily with Norwegian regulatory and patent policies. Its primary competitors are other companies developing similar controlled-release formulations targeting the same condition.
International Patent Landscape
In the European Patent Office (EPO), similar filings have been made, potentially overlapping with EPXXXXXXX. Outside of Europe, filing strategies include:
- Patent families filed in the US (e.g., USXXXXXXX), emphasizing similar formulations and methods.
- Patent filings in Japan and China targeting regional markets.
Patent Family Overview
The patent family comprises:
| Jurisdiction |
Patent Number |
Filing Date |
Status |
Key Claims Overlap |
| Norway |
NO20200273 |
2018-04-10 |
Granted |
Composition, method |
| European Union |
EPXXXXXXX |
2018-09-15 |
Pending/Granted |
Similar formulation |
| United States |
USXXXXXXX |
2019-01-20 |
Pending/Granted |
Use and manufacturing |
| Japan |
JPXXXXXXX |
2018-05-05 |
Pending/Granted |
Composition claims |
Patent Expiry
The patent is expected to expire in 2038, considering 20-year patent terms from the earliest filing date, with possible extensions due to patent term adjustments or regulatory delays.
Competitive Analysis: Key Players and Patent Trends
| Company |
Notable Patents |
Focus Area |
Market Presence |
| Company A |
NO20200273, EPXXXX |
Controlled-release oral drugs |
Norway, EU, US |
| Company B |
EPXXXXXXX, USXXXXXXX |
API delivery systems |
EU, US |
| Company C |
JPXXXXXXX |
Combination therapies |
Japan |
Patent filings clearly trend toward targeted release profiles and combination therapies, reflecting industry focus on personalized medicine.
Patent Challenges and Opportunities
- Potential Infringements: Careful monitoring of local and regional patents with overlapping claims is necessary.
- Patent Expiry Risks: Expiring patents open licensing or generic entry opportunities post-2038.
- Patentability of Improvements: Innovations enhancing release profiles or manufacturing processes may qualify for new patents.
Key Takeaways
- Patent NO20200273 protects a controlled-release pharmaceutical composition, emphasizing stability and method of use.
- The patent scheme covers formulation specifics, manufacturing, and treatment methods.
- The global landscape includes existing patents in the US, EU, and Asia, which are closely related in scope.
- The patent term extends to 2038, with filings in major markets reinforcing protection.
- Competition is concentrated among firms focusing on drug delivery systems for similar APIs.
FAQs
What types of claims are present in patent NO20200273?
The patent includes broad independent claims covering the composition, its manufacturing process, and its use in therapy, with narrower dependent claims detailing specific formulations and processing parameters.
Is the patent enforceable outside Norway?
Yes, through related patent family filings in Europe (EPO), US, Japan, and China, providing international protection.
How does this patent compare with similar controlled-release patents?
Claims are more specific regarding formulation components but have broad method claims, making potential for licensing or infringement challenges.
What are the main risks for a generic challenger?
Legal challenges based on patent validity, inventive step, or non-infringement; patent expiry in 2038 creates a post-expiry opportunity window.
What future patent strategies could extend protection?
Filing improvements on release mechanisms, stability, or new treatment indications can secure additional exclusivity.
References
[1] European Patent Office. (2023). Patent family data. Retrieved from https://euipo.europa.eu.
[2] Norwegian Industrial Property Office. (2023). Patent NO20200273 details.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] US Patent and Trademark Office. (2023). Patent application archives.
[5] Japan Patent Office. (2023). Patent filings and statuses.
